Zotatifin
| CAS No. | 2098191-53-6 | Cat. No. | BCP35487 |
| Name | Zotatifin | ||
| Synonyms | eFT226; eFT 226; eFT-226; | ||
| Formula | C28H29N3O5 | M. Wt | 487.56 |
| Description | Zotatifin (eFT226) is a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma. eFT226 promotes eIF4A1 binding to specific 5’-UTR polypurine and/or G-quadraplex recognition motifs leading to a selective block in ribosome mRNA scanning. eFT226 shows potent anti-proliferative activity (GI50 < 15 nM) against a panel of B-cell lymphoma cell lines. Treatment with eFT226 leads to coordinated inhibition of MYC, CCND1/3, BCL2 or MCL1 protein expression resulting in significant anti-tumor activity. | ||
| Pathways | Microbiology/Virology Cell Cycle/DNA Damage | ||
| Targets | SARS CoV eIF | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.